Moderna Competitors and Similar CompaniesClear all
Regulus Therapeutics's competitors and similar companies include Alnylam and Sarepta Therapeutics.
 Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | |
Founding Date | Founding Date 2007 | Founding Date 2002 | Founding Date 1980 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations San Diego, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | |
Employees | Employees 2462% decrease | Employees 1,32324% increase | Employees 1,31413% increase |
Valuation ($) | Valuation ($) 105.4 m | Valuation ($) 36.5 b | Valuation ($) 12.4 b |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $2.2b (FY, 2024) | Revenue (est.) $1.9b (FY, 2024) |
Net income | Net income ($46.4m) (FY, 2024) | Net income ($278.2m) (FY, 2024) | Net income $235.2m (FY, 2024) |
Funding | |||
Total funding raised | Total funding raised $ 10m | Total funding raised $ 1.5b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companySarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
View company